Denne øgede sensitivitet kan bl. a. manifestere sig ved konfusion, bevidsthedssvækkelse og postural ustabilitet med hyppige fald samt ekstrapyramidale symptomer.
The length of the oral supplementation period was also discussed and the CHMP concluded that 3 weeks is the most appropriate length, leading neither to an overdose at the end of the oral supplementation period in those patients who have a relatively early release, nor to clinically relevant ‘ underdosing’ in patients for whom the main release starts from 4 weeks onwards only, given the relatively long half-life of the active moiety following oral risperidone.